In the conclusion of this Exclusive Interview, Dr. Karl Nadolsky shares his treatment philosophy for lowering a patient's A1C down without being too aggressive. Dr. Nadolsky talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas.

In this week's Homerun Slides, the conclusion of Dr. Stanley Schwartz's presentation on the beta-cell classification of diabetes and delaying the need for insulin.

It was a challenge to develop a computer model that could account for plasma dynamics in a compact but accurate package. The model was the simplest representation we could devise, which was based upon known physiology, and which could accurately describe moment-by-moment plasma dynamics. The model continues to thrive in that it continues to be the basis for a large number of clinical investigations (∼50 per year) as well as a robust literature related to its mathematical and computer characteristics

Years ago the number one reason to try something new in diabetes was to benefit the patient. This is what led to new insulins, oral medications and devices like insulin pumps and continuous glucose monitors. All was going well till the PBM’s got involved. Now it all about what is …

Antioxidants and other polyphenols present in coffee confer healthy benefits to the body, which may include lowering insulin resistance, inflammation and biomarkers of liver function.

The treatment of choice for obese T2D patients is weight loss.

Earlier initiation of diabetes medications can lead to reduced heart disease risk in type 2 patients.

Management of non-glycemic cardiovascular disease risk factors may have increasing benefits in an aging type 1 diabetes patient population with long-term hyperglycemia.

Guest Post by David Kliff, Diabetic Investor. New diabetes technology sounds promising, but will products like One Drop really change patients' -- or payers' -- behavior?

Which of the following are strict or relative contraindications to the use of some of the GLP-1 agonists? A. Multiple endocrine neoplasia (MEN) syndrome type 2 B. Personal or family history of medullar thyroid cancer C. Pancreatitis D. All of the above Follow the link to see the right answer.